iCell in the News
iCell Presents Positive New Follow-up Clinical Data Confirming BCMA CD19 cCAR Safely Delivers Long-term Medication Free Complete Remission from Systemic Lupus Erythematosus & Lupus Nephritis at EULAR 2024 [June 2024] Read More
iCell Gene Therapeutics Announces Positive Clinical Data from Investigator Initiated Phase 1 Trial Evaluating BCMA-CD19 Compound CAR in Patients with Systemic Lupus Erythematosus/Lupus Nephritis Published in Annals of the Rheumatic Diseases [May 2024] Read More
iCell Gene Therapeutics Announces cCAR-T Clinical Publication in Stem Cell Reviews and Reports Journal. (September 2021) Read More
Treatment of Aggressive T Cell Lymphoblastic Lymphoma/Leukemia Using Anti-CD5 CAR T Cells, published by Stem Cell Reports, January 2021) Read More
FDA awards grant to fund new clinical trials to advance the development of iCell Gene Therapeutics’ CD4CAR T cell therapy for the treatment of rare disease (October 2020) Read more
iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at 61st American Society of Hematology Annual Meeting. (Nov. 14, 2019) Read More
Targeting Relapse with CD19-CD123 Compound CAR Therapy. Yan, et al., accepted for publication, Nov. 2019. In press
First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: ASH (Nov 4, 2018): Update on Phase 1 Clinical Trial Read More
Presidential symposium of the European Hematology Association Congress (Jun 14, 2018): Report for the CLL1-CD33 cCAR here and a panel discussion Read More
A compound chimeric antigen receptor strategy for targeting multiple myeloma published in Leukemia. (Sep 27, 2017) Read More
iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at 61st American Society of Hematology Annual Meeting. (Nov. 14, 2019) Read More
Characterization of an anti-CD5 directed CAR T-cell against T-cell malignancies, accepted for publication, Stem Cell Reviews and Reports, Nov. 2019.
Stony Brook University, iCell Gene Therapeutics and University of Louisville collaborate on first in human clinical trial of CAR-T cells targeting CD4 protein for aggressive T-cell leukemia and lymphoma (Oct 7, 2018) Read More
iCell Gene Therapeutics receives Orphan Drug Designation for CD5CAR for treatment of T-cell leukemia and lymphomas that are positive for CD5. (Oct 16, 2017)
iCell Gene Therapeutics receives Orphan Drug Designation for CAR-T targeting peripheral T-cell lymphoma (PTCL) (Aug 11, 2016) Read more
CD4CAR T cell paper published in Leukemia (Nov 9, 2015) Read More
CD5CAR NK cell paper published in Leukemia (Feb 12, 2017) Read More
Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. Pinz KG, et al., Oncotarget. 2017 www.ncbi.nlm.nih.gov/pubmed/29348865 Read More
CD3CAR NK cell paper published in Oncotarget (Aug 31, 2016) Read More
